Sorrento Therapeutics has developed a transdermal drug delivery device with a microneedle assembly and reservoir for efficient drug administration. The device includes a pushing element to apply bilateral force for precise drug delivery through the skin. GlobalData’s report on Sorrento Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Sorrento Therapeutics, Personalized cancer vaccines was a key innovation area identified from patents. Sorrento Therapeutics's grant share as of January 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Transdermal drug delivery device with microneedle assembly and reservoir
A newly granted patent (Publication Number: US11883622B2) discloses a drug delivery device designed to administer medication through microneedles. The device comprises an outer housing with upper and lower portions, a microneedle assembly, a reservoir containing the drug formulation, a plunger, and a pushing element. In the un-actuated position, the microneedle assembly is recessed and spaced from the user's skin, while in the actuated position, the plunger moves to apply a force that brings the microneedle assembly into direct contact with the skin, allowing the drug formulation to be delivered effectively.
The patent also details variations of the drug delivery device, including different configurations of the reservoir, the transmission of force through the microneedle assembly without increasing pressure in the reservoir, and the use of a pushing element such as a spring to facilitate the movement of the device from un-actuated to actuated positions. The device is designed to ensure precise and controlled delivery of medication, with the force applied by the pushing element being transmitted through the reservoir to the microneedle assembly without affecting the pressure of the drug formulation. Additionally, the device features a housing with upper and lower portions, allowing the microneedle assembly to move independently, and includes mechanisms to prevent the transmission of force through certain regions of the device for optimal functionality.
To know more about GlobalData’s detailed insights on Sorrento Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.